TL-895 and KRT-232 Study in Acute Myeloid Leukemia

NCT04669067 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: TL-895
DRUG: KRT-232

Sponsor

Telios Pharma, Inc.

Collaborators

[object Object]